ACRS Aclaris Therapeutics Inc.

21.22
+0.55  (+3%)
Previous Close 20.67
Open 20.8
52 Week Low 0.7
52 Week High 25.48
Market Cap $1,071,910,794
Shares 50,514,175
Float 48,472,357
Enterprise Value $1,019,534,958
Volume 507,320
Av. Daily Volume 3,780,642
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ATI-1777-AD-201
Atopic dermatitis
Phase 2a
Phase 2a
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
ATI-450
Rheumatoid arthritis (RA)
Phase 2b
Phase 2b
Phase 2b trial to be initiated 2H 2021.
ATI-450
COVID-19
Phase 2a
Phase 2a
Phase 2a dosing commenced August 2020.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Phase 3
Phase 3
Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-502 (VITI-201 Topical)
Vitiligo
Phase 2
Phase 2
Development to be discontinued - noted August 8, 2019.
ATI-502 (ATI-50002-AA-201) - dose ranging
Alopecia areata
Phase 2
Phase 2
Phase 2 data did not meet primary endpoint - June 26, 2019.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Approved
Approved
Approval announced December 15, 2017.

Latest News

    • Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021
    • ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis
    • Public Offering of $103.5M in January 2021 Strengthens Balance Sheet 

    WAYNE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2020 and provided a corporate update.

    "As we reflect on 2020, we are proud of how we have progressed our immuno-inflammatory…

    • Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021
    • ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis
    • Public Offering of $103.5M in January 2021 Strengthens Balance Sheet 

    WAYNE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2020 and provided a corporate update.

    "As we reflect on 2020, we are proud of how we have progressed our immuno-inflammatory development programs," said Dr. Neal Walker, President & CEO of Aclaris. "We are very excited about the platform potential of ATI-450, an oral MK2 inhibitor which we have shown to inhibit TNFα, IL1β, and IL6. Given its novel mechanism, there are several immuno-inflammatory indications that ATI-450 may potentially address. We are also excited about the potential of our pipeline which is internally generated from KINect®, our proprietary drug discovery platform, for various immuno-inflammatory indications. We look forward to building on this momentum in 2021."

    Research and Development Highlights:

    The global COVID-19 pandemic continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its research and development and regulatory activities listed below.

    • ATI-450, an investigational oral small molecule MK2 inhibitor compound:



      • ATI-450-RA-201: A Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis.
        • Positive preliminary topline data announced in January 2021. In this trial, ATI-450 demonstrated durable clinical activity, as defined by a marked and sustained reduction in DAS28-CRP and improvement of ACR20/50/70 responses over 12 weeks. This clinical activity was further supported by pharmacodynamic analyses showing a marked and durable inhibition of TNFα, IL1β, IL6, and IL8 in ex vivo stimulated samples as well as an endogenous inflammation biomarker analysis which also demonstrated a marked and sustained inhibition of median concentrations of hsCRP, TNFα, IL6, IL8, and MIP1β in the treatment arm over the 12 week period.
        • ATI-450 was generally well tolerated. The most common adverse events (AE) (each reported in 2 subjects) were urinary tract infection (UTI), elevated lipids and ventricular extrasystoles, all of which were determined to be unrelated to treatment except for one UTI. There was one non-treatment-related serious adverse event (COVID-19) reported in the four-week safety follow-up phase of the trial in a subject who was no longer receiving treatment.
        • Aclaris intends to progress ATI-450 into a Phase 2b trial in moderate to severe rheumatoid arthritis in the second half of 2021.
        • Aclaris is currently evaluating additional potential indications driven by TNFα, IL1β and IL6 as part of its planned expansion of its Phase 2 immuno-inflammatory clinical development programs.



      • ATI-450-PKPD-102: A Phase 1, placebo-controlled, randomized, observer-blind clinical trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 at 80 mg and 120mg twice daily in health subjects.
        • Positive preliminary topline data announced in January 2021. Pharmacodynamic analysis demonstrated incremental cytokine suppression at these higher doses. ATI-450 was generally well tolerated. The most common AEs (reported by 2 or more subjects who received ATI-450) were headache, dizziness, nausea, parasthesia and, in the post-dosing safety follow-up phase of the trial, dry skin. These AEs were all mild in severity.
        • A final analysis of this trial is underway.



      • ATI-450-CAPS-201: A Phase 2a, multicenter, open-label, single-arm clinical trial to investigate the safety, tolerability, efficacy and pharmacodynamics of ATI-450 for the maintenance of remission in subjects with cryopyrin-associated periodic syndrome (CAPS) previously managed with anti-IL1 therapy. Due to the COVID-19 pandemic, subject enrollment in this trial was paused. As a result of the ongoing pandemic and given the positive preliminary topline data from the ATI-450-RA-201 trial, Aclaris has decided to focus its efforts and resources on other immuno-inflammatory diseases.
    • ATI-1777, an investigational topical "soft" Janus Kinase (JAK) 1/3 inhibitor compound:



      • ATI-1777-AD-201: An ongoing Phase 2a, multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial to investigate the efficacy, safety, tolerability and pharmacokinetics of ATI-1777 in subjects with moderate to severe atopic dermatitis. The primary endpoint is the percentage change from baseline in the Eczema Area and Severity Index (EASI) score at week 4. Data from this trial are expected mid-year 2021.
    • ATI-2138, an investigational oral ITK/TXK/JAK3 (ITJ) inhibitor compound:



      • Aclaris is developing ATI-2138 as a potential treatment for T-cell mediated diseases such as psoriasis and/or inflammatory bowel disease and expects to submit an Investigational New Drug Application for ATI-2138 in the second half of 2021.

    Financial Highlights:

    Liquidity and Capital Resources

    As of December 31, 2020, Aclaris had aggregate cash, cash equivalents, restricted cash and marketable securities of $54.1 million compared to $75.0 million as of December 31, 2019. The changes in cash and cash equivalents and marketable securities during the year included:

    • Net cash used in operating activities was $38.6 million resulting from net loss of $51.0 million and changes in operating assets and liabilities of $2.4 million, partially offset by non-cash adjustments of $14.7 million.



    • Net borrowings of $10.9 million pursuant to a Loan and Security Agreement.



    • Net proceeds of $7.7 million from the sale of 2.1 million shares of common stock under an equity line of credit agreement.

    In January 2021, Aclaris closed a public offering in which it sold approximately 6.3 million shares of common stock. Proceeds from the offering were $103.5 million, net of underwriting discounts, commissions and offering expenses. Aclaris anticipates that its cash, cash equivalents and marketable securities as of December 31, 2020 in combination with the proceeds from the January 2021 public offering will be sufficient to fund its operations through the end of 2023, without giving effect to any potential business development transactions or financing activities.

    Financial Results

    Fourth Quarter 2020

    • Net loss was $13.2 million for the fourth quarter of 2020 compared to $18.6 million for the fourth quarter of 2019. Loss from continuing operations was $13.6 million for the quarter ended December 31, 2020 compared to $19.2 million for the prior year period.

    • Total revenue was $1.6 million for the fourth quarter of 2020 compared to $1.1 million for the fourth quarter of 2019.



    • Research and development (R&D) expenses were $9.0 million for the quarter ended December 31, 2020 compared to $11.5 million for the prior year period.



      • The quarter-over-quarter decrease of $2.6 million was primarily the result of expenses related to Aclaris' legacy JAK inhibitors ATI-501 and ATI-502, including the substantial completion of Aclaris' various Phase 2 clinical trials, and the substantial completion of two pivotal Phase 3 clinical trials of A-101 45% Topical Solution in 2019.
    • General and administrative (G&A) expenses were $4.9 million for the quarter ended December 31, 2020 compared to $5.8 million for the prior year period.



      • The quarter-over-quarter decrease of $0.9 million was primarily the result of lower non-cash stock-based compensation expense resulting from headcount reductions. Stock-based compensation expense was $1.6 million compared to $2.6 million in the prior year period.

    Full Year 2020

    • Net loss was $51.0 million for the year ended December 31, 2020 compared to $161.4 million for the year ended December 31, 2019. Loss from continuing operations was $51.2 million for the year ended December 31, 2020 compared to $113.5 million for the prior year period. Income from discontinued operations was $0.1 million for the year ended December 31, 2020 compared to a loss from discontinued operations of $47.8 million for the year ended December 31, 2019.



    • Total revenue was $6.5 million for the year ended December 31, 2020 compared to $4.2 million for the year ended December 31, 2019.



    • R&D expenses were $31.7 million for the year ended December 31, 2020 compared to $64.9 million for the prior year period.



      • The decrease of $33.2 million was primarily the result of expenses related to ATI-501 and ATI-502, including the substantial completion of Aclaris' various Phase 2 clinical trials, and the substantial completion of two pivotal Phase 3 clinical trials of A-101 45% Topical Solution in 2019.
      • R&D expenses in 2020 included non-cash stock-based compensation expense of $2.9 million compared to $5.1 million in the prior year period.

    • G&A expenses were $20.5 million for the year ended December 31, 2020 compared to $27.8 million for the prior year period.



      • The decrease of $7.3 million was primarily the result of lower personnel and non-cash stock-based compensation resulting from headcount reductions.
      • G&A expenses in 2020 included non-cash stock-based compensation expense of $7.3 million compared to $10.3 million in the prior year period.

    • For the year ended December 31, 2019, there was also a $18.5 million non-cash charge for the impairment of goodwill.

    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

    Cautionary Note Regarding Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "intend," "may," "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Aclaris' drug candidates, including the availability of data from its clinical trials and timing for regulatory filings, and its belief that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations through the end of 2023. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, Aclaris' ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2020, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "SEC Filings" page of the "Investors" section of Aclaris' website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



    Aclaris Therapeutics, Inc.

    Consolidated Statements of Operations

    (unaudited, in thousands, except share and per share data)

     Three Months Ended Year Ended
     December 31, December 31,
     2020  2019  2020  2019 
    Revenues:           
    Contract research$1,413  $1,095  $5,786  $4,227 
    Other revenue 167      696    
    Total revenue 1,580   1,095   6,482   4,227 
                
    Costs and expenses:           
    Cost of revenue (1) 1,286   1,028   5,133   4,055 
    Research and development (1) 8,956   11,540   31,731   64,899 
    General and administrative (1) 4,898   5,809   20,530   27,827 
    Goodwill impairment          18,504 
    Total costs and expenses 15,140   18,377   57,394   115,285 
    Loss from operations (13,560)  (17,282)  (50,912)  (111,058)
    Other expense, net (219)  (1,895)  (424)  (2,484)
    Loss from continuing operations before income taxes (13,779)  (19,177)  (51,336)  (113,542)
    Income tax benefit (182)     (182)   
    Loss from continuing operations (13,597)  (19,177)  (51,154)  (113,542)
    Income (loss) from discontinued operations, net of tax (1) 424   583   139   (47,812)
    Net loss$(13,173) $(18,594) $(51,015) $(161,354)
    Net loss per share, basic and diluted$(0.30) $(0.45) $(1.20) $(3.90)
    Weighted average common shares outstanding, basic and diluted 43,588,095   41,405,657   42,539,293   41,323,921 
                
    (1) Amounts include stock-based compensation expense as follows:           
                
    Cost of revenue$218  $249  $946  $703 
    Research and development 727   358   2,919   5,091 
    General and administrative 1,559   2,581   7,342   10,288 
    Income (loss) from discontinued operations, net of tax    (7)     95 
    Total stock-based compensation expense$2,504  $3,181  $11,207  $16,177 





    Aclaris Therapeutics, Inc.

    Selected Consolidated Balance Sheet Data

    (unaudited, in thousands)

            
      December 31, 2020 December 31, 2019 
    Cash, cash equivalents, restricted cash and marketable securities $54,131 $75,015 
    Total assets  70,784  98,297 
    Total current liabilities  14,874  22,432 
    Total liabilities  33,134  28,385 
    Total stockholders' equity  37,650  69,912 

    Aclaris Contact

     



    Primary Logo

    View Full Article Hide Full Article
  1. WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a company overview at the following upcoming virtual investor conferences:

    • H.C. Wainwright Global Life Sciences Conference. Tuesday, March 9, 2021 at 7:00 a.m. ET. Management will be available March 9th and 10th throughout the day for virtual one-on-one meetings.
    • Oppenheimer 31st Annual Healthcare Conference. Tuesday, March 16, 2021 at 10:00 a.m. ET. Management will be available March 16th throughout the day for virtual one-on-one meetings.

    A live audio webcast…

    WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a company overview at the following upcoming virtual investor conferences:

    • H.C. Wainwright Global Life Sciences Conference. Tuesday, March 9, 2021 at 7:00 a.m. ET. Management will be available March 9th and 10th throughout the day for virtual one-on-one meetings.
    • Oppenheimer 31st Annual Healthcare Conference. Tuesday, March 16, 2021 at 10:00 a.m. ET. Management will be available March 16th throughout the day for virtual one-on-one meetings.

    A live audio webcast of each presentation may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. Each webcast will be archived for at least 30 days on the Aclaris website.

    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

    Aclaris Contact

     



    Primary Logo

    View Full Article Hide Full Article
  2. WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET. Management will be available February 25th throughout the day for virtual one-on-one meetings.

    A live audio webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

    About Aclaris Therapeutics, Inc.

    WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET. Management will be available February 25th throughout the day for virtual one-on-one meetings.

    A live audio webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

    Aclaris Contact



    Primary Logo

    View Full Article Hide Full Article
  3. Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical and medical device companies.

    Dr. Cha was previously a Managing Partner at Vivo Capital. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ:ASND) and KalVista Pharmaceuticals (NASDAQ:KALV), and has served on the boards of Aclaris Therapeutics (NASDAQ:ACRS), Biohaven Pharma (NYSE:BHVN), Menlo Therapeutics (NASDAQ:MNLO), Sierra Oncology (NASDAQ:SRRA), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (NASDAQ:BFRM, acquired by Merz…

    Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical and medical device companies.

    Dr. Cha was previously a Managing Partner at Vivo Capital. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ:ASND) and KalVista Pharmaceuticals (NASDAQ:KALV), and has served on the boards of Aclaris Therapeutics (NASDAQ:ACRS), Biohaven Pharma (NYSE:BHVN), Menlo Therapeutics (NASDAQ:MNLO), Sierra Oncology (NASDAQ:SRRA), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (NASDAQ:BFRM, acquired by Merz))), Biodel (NASDAQ:BIOD), and NextWave Pharmaceuticals (acquired by Pfizer).

    Dr. Cha is a co-founder of the annual Dermatology Summit and Dermatology Innovation Forum. He also worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.

    Dr. Cha received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.

    "We are excited to welcome Albert to the Life Sciences team," said Patrick Heron, Managing Partner at Frazier. "He is a highly experienced investor who will be critical in helping us continue to identify attractive public and private investments."

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm's Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

    For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

    View Full Article Hide Full Article
  4. WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.  In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 822,557 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $96.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise…

    WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.  In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 822,557 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $96.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option. The offering is expected to close on or about January 22, 2021, subject to customary closing conditions.  

    Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering. 

    A shelf registration statement relating to this offering was filed with the Securities and Exchange Commission (SEC) on March 13, 2020 and declared effective by the SEC on April 29, 2020.  The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.  A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov.  A final prospectus supplement and accompanying prospectus will be filed with the SEC.  When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for Aclaris Therapeutics, Inc., including statements about Aclaris' public offering related to expected gross proceeds and anticipated closing date, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all and such other factors as are set forth in the risk factors detailed in Aclaris' Annual Report on Form 10-K for the year ended December 31, 2019, Aclaris' Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Aclaris makes with the SEC from time to time.  In addition, the forward-looking statements included in this press release represent Aclaris' views as of the date hereof. Aclaris anticipates that subsequent events and developments will cause Aclaris' views to change. However, while Aclaris may elect to update these forward-looking statements at some point in the future, Aclaris specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Aclaris' views as of any date subsequent to the date hereof.

    Aclaris Contact



    Primary Logo

    View Full Article Hide Full Article
View All Aclaris Therapeutics Inc. News